Akili Inc (AKLI) Actualités

Form 8-K - Current report

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with ADHD Through a Video Game

Clinically proven to improve attention function, EndeavorOTCⓇ is the first and only digital therapeutic cleared by FDA as an over-the-counter...

Form SC TO-T - Tender offer statement by Third Party

Form SC TO-C - Written communication relating to an issuer or third party

Form SC14D9C - Written communication relating to third party tender offer

Form SC14D9C - Written communication relating to third party tender offer

Form 8-K - Current report

Virtual Therapeutics, Akili Interactive Enter Into Definitive Merger Agreement to Establish Leading Digital Health Company

Akili to operate as wholly owned subsidiary of Virtual Therapeutics Virtual Therapeutics, a company focused on improving mental health at scale...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Akili Reports First Quarter 2024 Financial Results and Provides Business Update

Company announces full voluntary prepayment of debt and termination of Amended & Restated Loan and Security Agreement with Silicon Valley...

Form 4 - Statement of changes in beneficial ownership of securities

Akili Announces Amended Agreement with Shionogi, Shift in Corporate Strategy and Release Date for First Quarter 2024 Financial Results

Shionogi amendment provides Akili with near-term cash payments and cancellation of debt obligation Company announces exploration of strategic...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material